-
公开(公告)号：US08906367B2
公开(公告)日：2014-12-09
申请号：US12522031
申请日：2008-01-07
申请人： Roger Nitsch , Christoph Hock , Christoph Esslinger , Marlen Knobloch , Kathrin Tissot , Jan Grimm
发明人： Roger Nitsch , Christoph Hock , Christoph Esslinger , Marlen Knobloch , Kathrin Tissot , Jan Grimm
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/00 , C07K2317/21 , C07K2317/77
摘要： Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.
摘要翻译： 提供了新型特异性结合分子，特别是人抗体以及其识别疾病相关蛋白的新表型的片段，衍生物和变体，其衍生自天然内源性蛋白质，但是在变体形式和/或出口的患者体内普遍存在 的正常生理环境。 此外，描述了包含这样的结合分子的药物组合物，其抗体及其模拟物以及筛选新结合分子的方法，其可以是或可以不是抗体以及治疗神经疾病如阿尔茨海默病的靶标。
-
公开(公告)号：US20150147343A1
公开(公告)日：2015-05-28
申请号：US14322096
申请日：2014-07-02
申请人： Roger NITSCH , Christoph Hock , Christoph Esslinger , Marlen Knobloch , Kathrin Tissot , Jan Grimm
发明人： Roger NITSCH , Christoph Hock , Christoph Esslinger , Marlen Knobloch , Kathrin Tissot , Jan Grimm
CPC分类号： C07K16/18 , A61K39/3955 , A61K45/06 , A61K51/1018 , A61K2039/505 , C07K16/00 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , G01N33/6854 , G01N33/6896 , G01N2333/4709 , G01N2800/2821 , G01N2800/52
摘要： Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.
摘要翻译： 提供了新型特异性结合分子，特别是人抗体以及其识别疾病相关蛋白的新表型的片段，衍生物和变体，其衍生自天然内源性蛋白质，但是在变体形式和/或出口的患者体内普遍存在 的正常生理环境。 此外，描述了包含这样的结合分子的药物组合物，其抗体及其模拟物以及筛选新结合分子的方法，其可以是或可以不是抗体以及治疗神经疾病如阿尔茨海默病的靶标。
-
公开(公告)号：US20100202968A1
公开(公告)日：2010-08-12
申请号：US12522031
申请日：2008-01-07
申请人： Roger Nitsch , Christoph Hock , Christoph Esslinger , Marlen Knobloch , Kathrin Tissot , Jan Grimm
发明人： Roger Nitsch , Christoph Hock , Christoph Esslinger , Marlen Knobloch , Kathrin Tissot , Jan Grimm
IPC分类号： A61K49/00 , G01N33/50 , C07K16/00 , C07H21/00 , C12N15/74 , C12N5/10 , C12P21/02 , A61K31/7088 , A61K35/12 , A61K39/395 , A61K39/00 , A61P25/28
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/00 , C07K2317/21 , C07K2317/77
摘要： Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.
摘要翻译： 提供了新型特异性结合分子，特别是人抗体以及其识别疾病相关蛋白的新表型的片段，衍生物和变体，其衍生自天然内源性蛋白质，但是在变体形式和/或出口的患者体内普遍存在 的正常生理环境。 此外，描述了包含这样的结合分子的药物组合物，其抗体及其模拟物以及筛选新结合分子的方法，其可以是或可以不是抗体以及治疗神经疾病如阿尔茨海默病的靶标。
-
4.发明申请Immunoglobulin frameworks which demonstrate enhanced statbility in the intracellular envioronment and methods of identifying same 有权在细胞内环境中表现出增强的不稳定性的免疫球蛋白框架及鉴定其的方法公开(公告)号：US20060035320A1
公开(公告)日：2006-02-16
申请号：US10515241
申请日：2004-05-21
申请人： Kathrin Tissot , Stefan Ewert , Adrian Maur , Alcide Barberis , Dorminik Escher
发明人： Kathrin Tissot , Stefan Ewert , Adrian Maur , Alcide Barberis , Dorminik Escher
CPC分类号： C07K16/00 , A61K48/00 , C07K2317/21 , C07K2317/55 , C07K2317/567 , C07K2317/622 , C07K2317/80 , C07K2317/82 , C07K2317/94 , G01N33/6857
摘要： Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.
摘要翻译： 提供组合物，其可用作产生非常稳定和可溶性单链Fv抗体片段的框架。 这些框架已经被选择用于细胞内性能，因此理想地适用于产生scFv抗体片段或scFv抗体文库，用于其中稳定性和溶解度是抗体片段表现的限制因素，例如在细胞的还原环境中。 此类框架还可用于鉴定高度保守的残基和共有序列，这些序列表现出增强的溶解度和稳定性。
-
5.发明授权Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same 有权表现出在细胞内环境中增强的稳定性的免疫球蛋白框架及鉴定其的方法公开(公告)号：US08853362B2
公开(公告)日：2014-10-07
申请号：US10515241
申请日：2003-05-21
IPC分类号： C07K16/00
CPC分类号： C07K16/00 , A61K48/00 , C07K2317/21 , C07K2317/55 , C07K2317/567 , C07K2317/622 , C07K2317/80 , C07K2317/82 , C07K2317/94 , G01N33/6857
摘要： Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.
摘要翻译： 提供组合物，其可用作产生非常稳定和可溶性单链Fv抗体片段的框架。 这些框架已经被选择用于细胞内性能，因此理想地适用于产生scFv抗体片段或scFv抗体文库，用于其中稳定性和溶解度是抗体片段表现的限制因素，例如在细胞的还原环境中。 此类框架还可用于鉴定高度保守的残基和共有序列，这些序列表现出增强的溶解度和稳定性。
-
-
-
-
搜索结果
5 条记录 (耗时 0.025 秒)
